GSK Ends Pact with Vir For New COVID Treatments
Although Flu And Respiratory Collaboration Continues
Its Xevudy partner GSK is pulling out but Vir is going to carry on looking for new COVID-19 solutions independently, or with other partners.
You may also be interested in...
The beleaguered group is to cut its headcount and refocus on its hepatitis programs.
Public Company Edition: Follow-on offerings may not be the favored path to funding development programs or product launches after major milestones in the current environment. Amicus secured $430m in a deal with Blackstone, while OPKO’s Modex garnered up to $168m from BARDA.
Negative results from the PENINSULA study cast doubt on a Phase Ib study of the antibody in elderly adults. The company unveiled its next-generation flu drug, VIR-2981.